SITC Archive Library

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase Inhibitor, Combined with Nivolumab in Patients with Advanced Melanoma (MEL), Renal Cell Carcinoma (RCC), or Non-Small Cell Lung Cancer (NSCLC); Presenter: Funda Meric-Bernstam, MD – The University of Texas MD Anderson Cancer Center; Date: November 11, 2017
00:13:56

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combination with Pembrolizumab (PEMBRO) in Patients with Non-Small Cell Lung Cancer (NSCLC); Presenter: Leena Gandhi, MD, PhD – NYU Langone Medical Center; Date: November 11, 2017
00:08:23

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: OX40 T-cell Costimulatory Agonist BMS-986178 Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors: Initial Phase 1 Results); Presenter: Anthony J. Olszanski, MD – Fox Chase Cancer Center; Date: November 11, 2017
00:11:53

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab; Presenter: Jose Saro, MD – Roche Innovation Center Zurich; Date: November 11, 2017
00:10:30

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors; Presenter: Zev Wainberg, MD – UCLA School of Medicine; Date: November 11, 2017
00:15:33

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Infiltrating T Cell Expansion in Distant Lesions in a Phase 1/2 Study of Intratumoral IMO-2125+ipilimumab in Anti-PD1 Refractory Melanoma Patientss; Presenter: Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center; Date: November 11, 2017
00:13:10

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Pivot-02: Preliminary Safety, Efficacy and Biomarker Results from the Phase 1/2 Study of CD-122-Biased Agonist NKTR-214 Plus Nivolumab in Patients with Locally Advanced/Metastatic Solid Tumors; Presenter: Adi Diab, MD – The University of Texas MD Anderson Cancer Center; Date: November 11, 2017
00:12:23

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC); Presenter: Douglas McNeel, MD, PhD – University of Wisconsin; Date: November 11, 2017
00:12:21

Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation; Presenter: Jason Luke, MD – University of Chicago Medical Center; Date: November 11, 2017
00:10:38